76 related articles for article (PubMed ID: 17470918)
1. Selection of human immunodeficiency virus type 1 resistance against the pyranodipyrimidine V-165 points to a multimodal mechanism of action.
Hombrouck A; Hantson A; van Remoortel B; Michiels M; Vercammen J; Rhodes D; Tetz V; Engelborghs Y; Christ F; Debyser Z; Witvrouw M
J Antimicrob Chemother; 2007 Jun; 59(6):1084-95. PubMed ID: 17470918
[TBL] [Abstract][Full Text] [Related]
2. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
3. New class of HIV integrase inhibitors that block viral replication in cell culture.
Pannecouque C; Pluymers W; Van Maele B; Tetz V; Cherepanov P; De Clercq E; Witvrouw M; Debyser Z
Curr Biol; 2002 Jul; 12(14):1169-77. PubMed ID: 12176326
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
Hombrouck A; Van Remoortel B; Michiels M; Noppe W; Christ F; Eneroth A; Sahlberg BL; Benkestock K; Vrang L; Johansson NG; Barreca ML; De Luca L; Ferro S; Chimirri A; Debyser Z; Witvrouw M
Antimicrob Agents Chemother; 2008 Aug; 52(8):2861-9. PubMed ID: 18541726
[TBL] [Abstract][Full Text] [Related]
5. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
[TBL] [Abstract][Full Text] [Related]
6. Characterization of emergent HIV resistance in treatment-naive subjects enrolled in a vicriviroc phase 2 trial.
McNicholas P; Wei Y; Whitcomb J; Greaves W; Black TA; Tremblay CL; Strizki JM
J Infect Dis; 2010 May; 201(10):1470-80. PubMed ID: 20373959
[TBL] [Abstract][Full Text] [Related]
7. Selection and characterization of viruses resistant to the dual acting pyrimidinedione entry and non-nucleoside reverse transcriptase inhibitor IQP-0410.
Buckheit RW; Watson Buckheit K; Sturdevant CB; Buckheit RW
Antiviral Res; 2013 Nov; 100(2):382-91. PubMed ID: 24055450
[TBL] [Abstract][Full Text] [Related]
8. Oligonucleotide ligation assay for detection of mutations associated with reverse transcriptase and protease inhibitor resistance in non-B subtypes and recombinant forms of human immunodeficiency virus type 1.
Vega Y; Pérez-Alvárez L; Delgado E; Muñoz M; Casado G; Carmona R; Sierra M; Vázquez de Parga E; Pinilla M; García V; Medrano L; Contreras G; Thomson M; Nájera R
J Clin Microbiol; 2005 Oct; 43(10):5301-4. PubMed ID: 16208003
[TBL] [Abstract][Full Text] [Related]
9. Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A.
Witvrouw M; Fikkert V; Hantson A; Pannecouque C; O'keefe BR; McMahon J; Stamatatos L; de Clercq E; Bolmstedt A
J Virol; 2005 Jun; 79(12):7777-84. PubMed ID: 15919930
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase increase template-switching frequency.
Nikolenko GN; Svarovskaia ES; Delviks KA; Pathak VK
J Virol; 2004 Aug; 78(16):8761-70. PubMed ID: 15280484
[TBL] [Abstract][Full Text] [Related]
11. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.
Ogert RA; Wojcik L; Buontempo C; Ba L; Buontempo P; Ralston R; Strizki J; Howe JA
Virology; 2008 Apr; 373(2):387-99. PubMed ID: 18190945
[TBL] [Abstract][Full Text] [Related]
12. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
[TBL] [Abstract][Full Text] [Related]
13. Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naïve patients.
Hachiya A; Gatanaga H; Kodama E; Ikeuchi M; Matsuoka M; Harada S; Mitsuya H; Kimura S; Oka S
Virology; 2004 Oct; 327(2):215-24. PubMed ID: 15351209
[TBL] [Abstract][Full Text] [Related]
14. Revealing the drug-resistant mechanism for diarylpyrimidine analogue inhibitors of HIV-1 reverse transcriptase.
Zhang H; Qin F; Ye W; Li Z; Ma S; Xia Y; Jiang Y; Zhu J; Li Y; Zhang J; Chen HF
Chem Biol Drug Des; 2011 Sep; 78(3):427-37. PubMed ID: 21696545
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs.
Rai D; Chen W; Tian Y; Chen X; Zhan P; De Clercq E; Pannecouque C; Balzarini J; Liu X
Bioorg Med Chem; 2013 Dec; 21(23):7398-405. PubMed ID: 24134904
[TBL] [Abstract][Full Text] [Related]
16. Quantifying mixed populations of drug-resistant human immunodeficiency virus type 1.
Moser MJ; Ruckstuhl M; Larsen CA; Swearingen AJ; Kozlowski M; Bassit L; Sharma PL; Schinazi RF; Prudent JR
Antimicrob Agents Chemother; 2005 Aug; 49(8):3334-40. PubMed ID: 16048944
[TBL] [Abstract][Full Text] [Related]
17. Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360.
Fikkert V; Hombrouck A; Van Remoortel B; De Maeyer M; Pannecouque C; De Clercq E; Debyser Z; Witvrouw M
AIDS; 2004 Oct; 18(15):2019-28. PubMed ID: 15577623
[TBL] [Abstract][Full Text] [Related]
18. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.
Garvey EP; Johns BA; Gartland MJ; Foster SA; Miller WH; Ferris RG; Hazen RJ; Underwood MR; Boros EE; Thompson JB; Weatherhead JG; Koble CS; Allen SH; Schaller LT; Sherrill RG; Yoshinaga T; Kobayashi M; Wakasa-Morimoto C; Miki S; Nakahara K; Noshi T; Sato A; Fujiwara T
Antimicrob Agents Chemother; 2008 Mar; 52(3):901-8. PubMed ID: 18160521
[TBL] [Abstract][Full Text] [Related]
19. HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in Santos, Brazil.
de Sa-Filho DJ; Soares Mda S; Candido V; Gagliani LH; Cavaliere E; Diaz RS; Caseiro MM
AIDS Res Hum Retroviruses; 2008 Mar; 24(3):347-53. PubMed ID: 18327988
[TBL] [Abstract][Full Text] [Related]
20. Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.
Crespan E; Locatelli GA; Cancio R; Hübscher U; Spadari S; Maga G
Antimicrob Agents Chemother; 2005 Jan; 49(1):342-9. PubMed ID: 15616314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
